Business Context and Reporting Period
This Form 8-K Current Report was filed by Perspective Therapeutics, Inc. (NYSE American: CATX) on November 3, 2025. The filing discloses the execution of amended and restated employment agreements with three key executives: Johan (Thijs) Spoor (CEO), Jonathan Hunt (Chief Accounting Officer), and Dr. Markus Puhlmann (Chief Medical Officer). These agreements replace prior contracts entered into in 2023.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms. The following base salaries were confirmed as current under the new agreements:
- CEO (Johan Spoor): $680,000 annually
- Chief Accounting Officer (Jonathan Hunt): $451,500 annually
- Chief Medical Officer (Dr. Markus Puhlmann): $516,700 annually
Material Changes Versus Prior Period
The primary material change is the revision of Change in Control (CIC) provisions and the formalization of current base salaries. Key modifications include:
- Severance Enhancements: In the event of termination without Cause or resignation for Good Reason during the CIC Protection Period (3 months prior to 12 months post-CIC), executives are entitled to:
- 12 months of salary (18 months for the CEO).
- Pro-rated target annual discretionary bonus.
- An additional target annual discretionary bonus (1.5x for the CEO).
- COBRA premiums for up to 12 months (18 months for the CEO).
- Equity Acceleration: Upon qualifying termination during the CIC Protection Period, time-based equity awards vest fully, and performance-based awards vest at target levels. If equity awards are not assumed in a CIC, they vest fully (time-based) or at target (performance-based) provided the executive remains employed through the transaction.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of general business risks. The primary contingency noted is the requirement for executives to sign a release of claims to receive severance and equity acceleration benefits. The full text of the agreements will be filed in the Company's 2025 Form 10-K.
Investor Verification Checklist
- Verify the total potential cash and equity payout obligations for the CEO versus other executives in a Change in Control scenario.
- Review the 2025 Annual Proxy Statement (filed April 16, 2025) to compare the new terms against the previous 2023 agreements.
- Monitor the upcoming 2025 Form 10-K for the full text of the Amended and Restated Employment Agreements.
- Assess the impact of these enhanced severance packages on the company's cash reserves given its current financial position (not disclosed in this filing).